The cumulative earnings power of these 30 stocks was revised UP by 8.58% in the past 60 days.

The stock market has continued to edge higher and the two major indexes, the Nasdaq (QQQ) and S&P 500 (SPY​), touched the all-time high milestone last week.

The 2019 rally is fading with few clues as to what comes next. The narrative gets more complicated once a slower global economic outlook gets factored into the fundamentals.

Gene Therapy stocks soar on Spark (ONCE) Deal: BLUE, CRSP, RARE; and XBI up 4.2%.

Amarin Corporation, Plc. is up 467% since the end of September. Really, that’s the only way to start a story on this small biopharmaceutical company.

Sinocare, a diabetes company based in Changsha, may bid as much as $4 billion to acquire Johnson & Johnson's diabetes medical device subsidiaries. With falling revenues, some of J&J's diabetes-focused companies are exiting from the US market.

Cheap stocks can be a smart choice for investors, as there are serious bargains to be found. The stocks below may be cheap, but they all have significant support from Wall Street’s best-performing analysts.

The average ADR is trading -23.76% below its 52 week high, 2.83% above its 200 dma, has 3.72 days to cover held short, and is expected to grow its EPS by 17.58% next year.

PhotoMedex Inc. shares soared 24.5% in pre-market trading to $2.29 after the dermatological pharmaceutical company announced it will be selling two treatments to MELA Sciences in a $42.5 million cash deal.

Over the past week here are the stocks with the most bullish messages from the StockTwits community.

After some spring cleaning last week I added back a few positions to our New High Portfolio. I added Foot Locker, Transportadora De Gas, Alliant Techsystems, Amarin and Citigroup .

Eddingpharm, a China in-licensing company, signed a deal worth up to $169 million for China rights to Vascepa®, a prescription omega-3 drug from Amarin Corp and more Pharma/Biotech news.

If you think this is the start of a larger correction now is the time to start looking at stocks that have been weak on StockTwits and Twitter.

Covering the overnight markets and news you may have missed.